


Amendments in the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

Claim 1. (currently amended): A compound of formula I,



in which wherein

A is (C₁-C₈)alkyl, (C₀-C₈)alkylenearyl; a 3- to 12-membered mono- or bicyclic ring which may contain one or more heteroatoms selected from the group consisting of N, O, and S, and the 3- to 12-membered ring may carry further substituents selected from the group consisting of F, Cl, Br, NO₂, CF₃, OCF₃, CN, (C₁-C₆)alkyl, aryl, CON(R37)(R38), N(R39)(R40), OH, O-(C₁-C₆)alkyl, S-(C₁-C₆)alkyl, and NHCO(C₁-C₆)alkyl;

X is a bond, C(R8)(R9), C(OR10)(R11), O, N(R12), S, SO, SO₂, or CO;

R8, R9, R10, R11, R12 are, independently of one another, H, [], or (C₁-C₆)alkyl;

D is ~~N~~, or C(R41);

E is ~~N~~, or C(R42);

G is ~~N~~, or C(R43);

L is ~~N, or~~ C(R44);

R1, R2, R3, R41, R42, R43, R44 are, independently of one another, H, F, Cl, Br, J, OH, CF₃, NO₂, CN, OCF₃, O-(C₁-C₆)alkyl, (C₁-C₄)alkoxyalkyl, S-(C₁-C₆)alkyl, (C₁-C₆)alkyl, (C₂-C₆)alkenyl, (C₃-C₈)cycloalkyl, O-(C₃-C₈)cycloalkyl, (C₃-C₈)cycloalkenyl, O-(C₃-C₈)cycloalkenyl, (C₂-C₆)alkynyl, (C₀-C₈)alkylenearyl, -O-(C₀-C₈)alkylenearyl, S-aryl, N(R13)(R14), SO₂-CH₃, COOH, COO-(C₁-C₆)alkyl, CON(R15)(R16), N(R17)CO(R18), N(R19)SO₂(R20), CO(R21), or a 5- to 7-membered heterocycle having 1-4 heteroatoms;

R13, R14 are, independently of one another, H, (C₁-C₆)alkyl, or R13 and R14, together with the nitrogen atom to which they are bonded, form a 5- to 6-membered ring, wherein, in the case of the 6-membered ring, a CH₂ group may be replaced by O or S;

R15, R16 are, independently of one another, H, (C₁-C₆)alkyl, or R15 and R16, together with the nitrogen atom to which they are bonded, form a 5- to 6-membered ring, wherein, in the case of the 6-membered ring, a CH₂ group may be replaced by O or S;

R17, R19 are, independently of one another, H[[,]] or (C₁-C₆)alkyl;

R18, R20, R21 are, independently of one another, (C₁-C₆)alkyl, or aryl;

B is N(R24)[[,]] or O;

R24 is H[[,]] or (C₁-C₆)alkyl;

R5 is H[[,]] or (C₁-C₆)alkyl;

W is ~~N, or C(R25)~~;

~~R25 is H, (C₁-C₆)alkyl, aryl, or a bond to Y;~~

T is ~~N, or~~ C(R26);

R26 is H, (C₁-C₆)alkyl, aryl, (C₀-C₈)alkylenearyl, or a bond to Y;

U is ~~O, S, N(R27), -C(R30)=N, or N=C(R31)~~;

R27, ~~R30, R31~~ are is independently of one another H, (C₁-C₆)alkyl, or a bond to Y;

Y is (C₁-C₈)alkylene, in which one or more carbons may be replaced by O, S, SO, SO₂, C(R32)(R33), CO, C(R34)(OR35)₂ or N(R36);

R32, R33, R34, R35, R36 are, independently of one another, H, (C₁-C₆)alkyl, or aryl;

R6, R7 are, independently of one another, H, (C₁-C₆)alkyl, (C₃-C₇)cycloalkyl, or R6 and Y or R6 and R7, together with the nitrogen atom to which they are bonded, form a 3- to 8-membered ring in which one or more carbons may be replaced by O, N₂ or S₂ and the 3- to 8-membered ring may carry further substituents such as (C₁-C₆)alkyl, aryl, CON(R37)(R38), N(R39)(R40), OH, O-(C₁-C₆)alkyl, or NHCO(C₁-C₆)alkyl;

R37, R38, R39, R40 are, independently of one another, H[[,]] or (C₁-C₆)alkyl; and the physiologically acceptable salts thereof.

Claim 2. (currently amended): **[[A]]** The compound of ~~formula I as claimed in~~ claim 1, wherein

A is (C₂-C₇)alkyl, (C₀-C₃)alkylenearyl; a 4- to 10-membered mono- or bicyclic ring which may contain one or more heteroatoms selected from the group consisting of N, O, and S, and the 4- to 10-membered ring may carry further substituents selected from the group consisting of F, Cl, Br, NO₂, CF₃, (C₁-C₆)alkyl, aryl, CON(R37)(R38), N(R39)(R40), O-(C₁-C₆)alkyl, and NHCO(C₁-C₆)alkyl;

X is a bond, C(R8)(R9), O, N(R12), S, or SO₂;

R8, R9, R12 are, independently of one another, H[[,]] or (C₁-C₆)alkyl;

D is ~~N, or~~ C(R41);

E is ~~N, or~~ C(R42);

G is ~~N, or~~ C(R43);

L is ~~N, or~~ C(R44);

~~where the total number of the nitrogen atoms defined by D, E, G and L is 0, 1 or 2;~~

R1, R2, R3, R41, R42, R43, R44 are, independently of one another, H, F, Cl, Br, CF₃, NO₂, O-(C₁-C₆)alkyl, (C₁-C₆)alkyl, (C₃-C₈)cycloalkyl, O-(C₃-C₈)cycloalkyl, (C₂-C₆)alkynyl, (C₀-C₈)alkylenearyl, -O-(C₀-C₃)alkylenearyl, S-aryl, N(R13)(R14), SO₂-CH₃, COO-(C₁-C₆)alkyl, CON(R15)(R16), N(R17)CO(R18), N(R19)SO₂(R20), or CO(R21);

R13, R14 are, independently of one another, H, (C₁-C₆)alkyl, or R13 and R14, together with the nitrogen atom to which they are bonded, form a 5- to 6-membered ring, wherein, in the case of the 6-membered ring, a CH₂ group may be replaced by O or S;

R15, R16 are, independently of one another, H, (C₁-C₆)alkyl, or R15 and R16, together with the nitrogen atom to which they are bonded, form a 5- to 6-membered ring, wherein, in the case of the 6-membered ring, a CH₂ group may be replaced by O or S;

R17, R19 are, independently of one another, H, or (C₁-C₆)alkyl;

R18, R20, R21 are, independently of one another, (C₁-C₆)alkyl, or aryl;

B is N(R24)[[₁]] or O;

R24 is H[[₁]] or (C₁-C₆)alkyl;

R5 is H[[₁]] or (C₁-C₆)alkyl;

W is ~~N, or C(R25)~~;

~~R25 is H, (C₁-C₆)alkyl, or aryl;~~

T is C(R26);

R26 is H, (C₁-C₆)alkyl, aryl, or a bond to Y;

U is ~~O, S, N(R27), or N=C(R31)~~;

~~R27, R31 are independently of one another~~ is H, (C₁-C₆)alkyl, or a bond to Y;

Y is (C₁-C₄)alkylene, in which a carbon may be replaced by SO₂, C(R32)(R33), CO₂ or N(R36);

R32, R33, R36 are, independently of one another, H, (C₁-C₆)alkyl, or aryl;

R6, R7 are, independently of one another, H, (C₁-C₆)alkyl, (C₃-C₇)cycloalkyl, or R6 and Y or R6 and R7, together with the nitrogen atom to which they are bonded, form a 4- to 7-membered ring in which one or more carbons may be replaced by O, N, or S, and the 4- to 7-membered ring may carry further substituents selected from the group consisting of (C₁-C₆)alkyl, aryl, CON(R37)(R38), N(R39)(R40), OH, and NHCO(C₁-C₆)alkyl;

R37, R38, R39, R40 are, independently of one another, H, or (C₁-C₆)alkyl;
and the physiologically acceptable salts thereof.

Claim 3. (currently amended): [[A]] ~~The~~ compound of ~~formula I as claimed in~~ either of claims 1 ~~and or~~ 2, wherein

A is (C₃-C₇)alkyl, (C₀-C₂)alkylenearyl; a 5- to 10-membered mono- or bicyclic ring which may contain 0, 1, or 2 heteroatoms selected from the group consisting of N, O, and S, and the 5- to 10-membered ring may carry further substituents selected from the group consisting of F, Cl, Br, NO₂, CF₃, (C₁-C₆)alkyl, aryl, O-(C₁-C₆)alkyl, and NHCO(C₁-C₆)alkyl;

X is a bond, C(R8)(R9), O, or N(R12);

R8, R9, R12 are, independently of one another, H, [[,]] or (C₁-C₆)alkyl;

D is ~~N,~~ or C(R41);

E is ~~N,~~ or C(R42);

G is ~~N,~~ or C(R43);

L is ~~N,~~ or C(R44);

~~where the total number of the nitrogen atoms defined by D, E, G and L is 0 or 1;~~

R1, R2, R3, R41, R42, R43, R44 are, independently of one another, H, F, Cl, CF₃, NO₂, O-(C₁-C₆)alkyl, (C₁-C₆)alkyl, O-(C₃-C₈)cycloalkyl, (C₀-C₂)alkylenearyl, -O-(C₀-C₃)alkylenearyl, N(R13)(R14), COO-(C₁-C₆)alkyl, CON(R15)(R16), N(R17)CO(R18), N(R19)SO₂(R20), or CO(R21);

R13, R14 are, independently of one another, H[,] or (C₁-C₆)alkyl[,,];

R15, R16 are, independently of one another, H[,] or (C₁-C₆)alkyl[,,];

R17, R19 are, independently of one another, H[,] or (C₁-C₆)alkyl;

R18, R20, R21 are, independently of one another, (C₁-C₆)alkyl, or aryl;

B is N(R24);

R24 is H[,] or (C₁-C₆)alkyl;

R5 is H[,] or (C₁-C₆)alkyl;

W is N, ~~or C(R25)~~;

~~R25 is H, or (C₁-C₆)alkyl;~~

T is C(R26);

R26 is H, (C₁-C₆)alkyl, or a bond to Y;

U is ~~O, S~~, N(R27);

R27 is H, (C₁-C₆)alkyl, or a bond to Y;

Y is (C₁-C₃)alkylene, in which a carbon may be replaced by SO₂, C(R32)(R33) or CO;

R32, R33 are, independently of one another, H, (C₁-C₆)alkyl, or aryl;

R6, R7 are, independently of one another, H, (C₁-C₆)alkyl, (C₃-C₇)cycloalkyl, or R6 and Y or R6 and R7, together with the nitrogen atom to which they are bonded, form a 5- or 6-membered ring in which one or more carbons may be replaced by O or N, and the 5- or 6-

membered ring may carry further substituents selected from the group consisting of (C₁-C₆)alkyl, aryl, CON(R37)(R38), N(R39)(R40), OH and NHCO(C₁-C₆)alkyl;

R37, R38, R39, R40 are, independently of one another, H, or (C₁-C₆)alkyl;
and the physiologically acceptable salts thereof.

Claim 4. (currently amended): A pharmaceutical composition comprising one or more of the compounds ~~as claimed in~~ of claim 1 and a physiologically acceptable carrier.

Claim 5. (canceled)

Claim 6. (currently amended): A method for the prophylaxis or treatment of obesity, comprising administering to a mammal in need thereof an effective amount of [[a]] the compound ~~as claimed in~~ of claim 1, or a physiologically acceptable salt thereof.

Claim 7. (currently amended): A method for the prophylaxis or treatment of type II diabetes, comprising administering to a mammal in need thereof an effective amount of [[a]] the compound ~~as claimed in~~ of claim 1, or a physiologically acceptable salt thereof.

Claims 8-9. (canceled)

Claim 10. (currently amended): A method for preparing a pharmaceutical composition, comprising one or more of the compounds ~~as claimed~~ of claim 1, [[which]] compris[[es]]ing mixing the active substance with a pharmaceutically suitable carrier and bringing said mixture into a form suitable for administration.

Claim 11. (currently amended): A method for the prophylaxis or treatment of arteriosclerosis or high blood pressure, comprising administering to a mammal in need thereof an effective amount of **[[a]] the compound ~~as claimed in of~~ claim 1**, or a physiologically acceptable salt thereof.

Claim 12. (currently amended): A method for normalizing lipid metabolism, comprising administering to a mammal in need thereof an effective amount of **[[a]] the compound ~~as claimed in of~~ claim 1**, or a physiologically acceptable salt thereof.

Claim 13. (currently amended): A method for the prophylaxis or treatment of paresthesia, depression, anxiety, anxiety neuroses, or schizophrenia, comprising administering to a mammal in need thereof an effective amount of **[[a]] the compound ~~as claimed in of~~ claim 1**, or a physiologically acceptable salt thereof.

Claim 14. (currently amended): A method for the prophylaxis or treatment of disorders associated with the circadian rhythm, comprising administering to a mammal in need thereof an effective amount of **[[a]] the compound ~~as claimed in of~~ claim 1**, or a physiologically acceptable salt thereof.

Claim 15. (currently amended): A method for the treatment of drug abuse, comprising administering to a mammal in need thereof an effective amount of **[[a]] the compound ~~as claimed in of~~ claim 1**, or a physiologically acceptable salt thereof.